Molecular Infectious Disease Testing Market worth $17.78 billion by 2029
The report "Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2029", molecular infectious disease testing market is valued at an estimated USD 9.37 billion in 2024 and is projected to reach USD 17.78 billion by 2029 at a CAGR of 13.7% during the forecast period.
Browse 539 market data Tables and 61 Figures spread through 448 Pages and in-depth TOC on "Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/molecular-infectious-disease-testing-market-40667482.html
The molecular infectious disease testing market is growing rapidly primarily driven by the increasing burden of infectious diseases across the world. Rising number of cases of infectious diseases, such as HIV, influenza, hepatitis, coupled with emerging infections, increase the demand for more accurate and efficient diagnostic solutions. Along with this, there is a growing interest in R&D in the field of molecular diagnostics, which results in the development of more sophisticated and accurate testing technologies. Growing funding for research and innovations in molecular testing has accelerated the rate of progress in this area and enabled more efficient methods of detection. Rapid technological advancements in multiplex testing, PCR, and next-generation sequencing are further driving the market's growth, allowing for quicker, more reliable diagnostics and improved patient outcomes around the world.
In 2023, PCR dominated the molecular infectious disease testing market by technology segment.
Based on technology, the molecular infectious disease testing market is divided into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing (NGS), in situ hybridization, DNA microarrays, and other technologies. The PCR segment dominated the molecular infectious disease testing market in the year 2023, which is primarily attributed to the high sensitivity and reliability of this technique in the detection of various pathogens. Since PCR has been proven as a reliable, sensitive method in diagnostics, it has been widely accepted in molecular infectious disease testing. The availability of well-optimized protocols along with high-quality commercial kits and reagents has made it simpler to use in laboratories. Advancements in the automation of PCR systems further increased its efficiency, and it became the preferred choice for diagnostic labs seeking to deliver fast, accurate results. The increased demand for testing solutions that are accurate and efficient is what drives the dominance of PCR as one of the primary technologies in facing the increasing problems in infectious disease management and detection.
Diagnostic laboratories are the fastest growing end user segment of the molecular infectious disease testing market.
The molecular infectious disease testing market is segmented into diagnostic laboratories, hospitals & clinics, and other end-users, based on end user. Diagnostic laboratories are the most rapidly growing segment among end-users in the molecular infectious disease testing market. Growth of this end user segment can be attributed to enhanced demand for accurate and rapid diagnostic solutions, as the burden of infectious diseases continues to rise globally. With the growing focus on precise pathogen identification, diagnostic labs are increasingly adopting advanced molecular testing methods including PCR, multiplex, and other new assays to identify pathogens quickly. Moreover, increased emphasis on early disease detection, especially because of global health crises, resulted in a high surge in demand for molecular diagnostics that positions diagnostic labs as the fastest growing end user segment in the market.
North America is the largest regional market for molecular infectious disease testing.
The market for molecular infectious disease testing has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. In 2023, North America dominated the molecular infectious disease testing market, primarily because this region has a superior healthcare infrastructure combined with an ease of accessibility for advanced diagnostic technologies and emphasis on research and development. Furthermore, robust disease surveillance systems and outbreak control measures have significantly enhanced the ability of the region to respond to the growing infectious diseases burden, which have further increased the demand for more accurate and efficient molecular diagnostic tests. Moreover, the presence of major industry players, robust regulatory frameworks, and high investments in healthcare innovation are all factors that support North America's leading position in this market.
The major players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Molecular Infectious Disease Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
